Latest Research
All publications from the Cancer3.AI database, newest first.
Molecular Subtypes and Prognostic Biomarkers of Breast Carcinoma in Different Age Groups: Findings from a Tertiary Care Hospital in Saudi Arabia.
Aamir S, et al
A retrospective study conducted at a tertiary care hospital in Riyadh, Saudi Arabia analyzed clinicopathological and immunohistochemical features of breast cancer in 300 female patients diagnosed between 2017 and 2022, comparing younger women aged 40 years or under with those over 40. Researchers found that younger patients presented with significantly more aggressive disease, including larger tumors, more advanced staging, higher Ki-67 proliferation index, and greater lymph node involvement at diagnosis. Triple-negative breast cancer, a subtype with fewer treatment options and poorer outcomes, was significantly more prevalent among younger patients, while the less aggressive Luminal A subtype was more common in older women. Cox regression analysis identified advanced disease stage and triple-negative receptor status as the strongest independent predictors of mortality, with hazard ratios exceeding 11-fold compared to early-stage and Luminal A tumors. These findings highlight the need for targeted screening strategies and age-specific treatment approaches in Saudi Arabia, where young-onset breast cancer appears to carry a distinctly aggressive biological profile.
Saudi journal of medicine & medical sciences
Source →Identifying parathyroid carcinoma patients eligible for conservative surgery in the form of primary tumor resection while maintaining oncological safety.
Chen Z, et al
Researchers investigated whether patients with parathyroid carcinoma — a rare malignancy of the parathyroid glands — could safely undergo a less extensive surgical procedure known as primary tumor resection, rather than the more radical en-bloc resection that removes surrounding tissues. Using data from 451 patients drawn from the large U.S. SEER database (2000–2021) and a Chinese hospital cohort (2013–2024), the team analyzed which clinical and pathological factors influenced disease-specific survival. Multivariate analysis identified tumor size greater than 30 mm and the presence of distant metastasis as independent predictors of poorer outcomes. Crucially, after propensity score matching, patients with tumors 30 mm or smaller and no regional lymph node spread showed no significant difference in survival whether they underwent the conservative or the radical operation. These findings suggest that a substantial subset of parathyroid carcinoma patients can safely avoid overly aggressive surgery, potentially reducing surgical complications and improving quality of life without compromising cancer control.
Updates in surgery
Source →Primary Central Nervous System Lymphoma With Testicular and Prostatic Involvement: A Case Report.
Rodríguez Morales JA, et al
Researchers report a rare case of primary central nervous system diffuse large B-cell lymphoma (CNS DLBCL) in a 41-year-old immunocompetent man who presented with left-sided weakness, facial palsy, severe headache, and reduced consciousness. Brain imaging and tissue biopsy confirmed the CNS lymphoma diagnosis, while a full-body PET-CT scan revealed additional tumor involvement in the testicles and prostate, indicating early systemic spread of the disease. The patient was treated with the MATRIX chemotherapy protocol, which combines high-dose methotrexate, cytarabine, and rituximab, consistent with current treatment guidelines for primary CNS lymphoma. This case is notable because simultaneous CNS, testicular, and prostatic involvement in an immunocompetent patient is exceptionally uncommon and highlights the aggressive dissemination potential of DLBCL. The report underscores the critical importance of thorough whole-body staging at diagnosis, as occult extranodal disease may be present even when symptoms appear confined to the brain. Early and comprehensive evaluation can guide more effective treatment decisions and potentially improve patient outcomes.
Cureus
Source →Exploring CSF microRNA signatures as diagnostic biomarkers in adult-type diffuse gliomas.
Pirhoushiaran M, et al
Researchers investigated whether small RNA molecules called microRNAs, found in the cerebrospinal fluid (CSF) of brain tumor patients, could serve as minimally invasive diagnostic biomarkers for diffuse gliomas — a group of aggressive brain cancers classified by mutations in the IDH gene. Using microRNA sequencing, quantitative PCR, and logistic regression analysis on CSF samples, the team identified specific microRNA signatures that could reliably distinguish between tumor subtypes and healthy controls. A single microRNA, miR-142-3p, achieved perfect discrimination between IDH-mutant gliomas and non-tumor samples, while a five-microRNA panel perfectly separated IDH-wildtype from IDH-mutant tumors, and nine reduced microRNAs accurately identified glioblastoma. These findings are significant because current glioma diagnosis requires invasive brain biopsies; a CSF-based liquid biopsy approach using microRNAs could enable less invasive molecular characterization of brain tumors, potentially improving diagnostic accuracy and guiding treatment decisions for patients.
Non-coding RNA research
Source →A Recurrent Middle Ear Neuroendocrine Tumor Mimicking a Paraganglioma: A Case Highlighting Diagnostic Challenges.
Graboyes AZ, et al
A case report published in Otology & Neurotology describes a rare and diagnostically challenging presentation of a recurrent neuroendocrine tumor of the middle ear that closely resembled a paraganglioma, a more commonly recognized vascular tumor of that anatomical region. Middle ear neuroendocrine tumors are uncommon neoplasms that can be easily misidentified due to overlapping clinical and imaging features with paragangliomas, potentially leading to inappropriate treatment strategies. This case underscores the importance of thorough histopathological and immunohistochemical evaluation when a middle ear mass recurs after initial treatment, as the tumor type dictates the correct surgical and oncological approach. For clinicians, this report serves as a reminder that rare neuroendocrine tumors must be included in the differential diagnosis of middle ear masses, especially in recurrent cases where initial diagnoses may need to be reconsidered. Accurate diagnosis is essential to ensure patients receive appropriate management and adequate follow-up for a condition that carries its own distinct recurrence risk and prognosis.
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
Source →